Bulletin from the extraordinary general meeting of OptiCept Technologies AB (publ) on 18 December 2025

About this update from Opticept Technologies Ab

OptiCept Technologies AB (publ) (the “Company” or “OptiCept”) held an Extraordinary General Meeting on 18 December 2025. At the general meeting, the following resolutions were adopted, among others.N.B. The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.Determination of the number of Board members any deputy Board members and election of the Board of Directors and any deputy Board membersThe general meeting resolved, in accordance with the Nomination Committee's proposal, that the Board shall consist of seven (7) Board members without deputies.In accordance with the Nomination Committee's proposal, Ulf Hagman, Nicklas Margård, Carlos Fernandez Villena, Kees Jansen van Rosendaal and Eda Demir Westman were re-elected as Board members for the period until the next Annual General Meeting. In accordance with the Nomination Committee's proposal, Mikael Carleson and Jörgen Durban were elected as new Board members.Ulf Hagman was re-elected as Chairman of the Board and Nicklas Margård was re-elected as Vice Chairman of the Board.Fees for the BoardThe general meeting resolved, in accordance with the Nomination Committee's proposal, that the new Board members shall receive remuneration in accordance with the remuneration levels resolved by the Annual General Meeting on 22 May 2025 and that Board fees shall be paid pro rata for the period during which the member holds the position, calculated from the date of appointment until the end of the next Annual General Meeting.Resolution on the Board of Directors' proposal for a directed issue of warrants to lendersThe general meeting resolved, in accordance with the Board's proposal, to issue a maximum of 1,878,979 warrants of series TO8, entailing an increase in share capital upon full exercise of a maximum of SEK 169,108.11.The right to subscribe for the warrants is granted, with deviation from the shareholders’ preferential rights, to Rickard Rönblom, JJV Investment Group AB, Vellenova AB, Christer Jönsson, Andreas Jahn, Björn Wetterling, Business Remedy Associates Sweden AB, Mikael Blihagen, Med Tech Invest Europe AB, JEQ Capital AB, Curam Holding AB and Quantum Leben AG.The directed issue of warrants is a prerequisite for the loan announced by the Company on 23 November 2025, through which the Company refinance...

View stock analysis, news, and events for Opticept Technologies Ab